Log in
NASDAQ:KMPH

KemPharm Stock Forecast, Price & News

$0.54
+0.02 (+3.85 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.52
Now: $0.54
$0.56
50-Day Range
$0.50
MA: $0.66
$0.74
52-Week Range
$0.12
Now: $0.54
$0.93
Volume201,787 shs
Average Volume1.87 million shs
Market Capitalization$39.15 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. It also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. The company has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. KemPharm, Inc. was founded in 2006 and is headquartered in Celebration, Florida.
Read More
KemPharm logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.03 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KMPH
CUSIPN/A
Phone321-939-3416
Employees33

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.84 million
Book Value($1.04) per share

Profitability

Net Income$-24,520,000.00

Miscellaneous

Market Cap$39.15 million
Next Earnings Date11/12/2020 (Estimated)
OptionableOptionable
$0.54
+0.02 (+3.85 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for KMPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











KemPharm (NASDAQ:KMPH) Frequently Asked Questions

How has KemPharm's stock price been impacted by Coronavirus (COVID-19)?

KemPharm's stock was trading at $0.2452 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KMPH shares have increased by 120.2% and is now trading at $0.5399.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of KemPharm?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for KemPharm
.

When is KemPharm's next earnings date?

KemPharm is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for KemPharm
.

How were KemPharm's earnings last quarter?

KemPharm Inc (NASDAQ:KMPH) announced its earnings results on Wednesday, August, 12th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $6.91 million during the quarter, compared to analyst estimates of $6.75 million.
View KemPharm's earnings history
.

What price target have analysts set for KMPH?

1 Wall Street analysts have issued twelve-month price objectives for KemPharm's shares. Their forecasts range from $1.50 to $1.50. On average, they expect KemPharm's stock price to reach $1.50 in the next year. This suggests a possible upside of 177.8% from the stock's current price.
View analysts' price targets for KemPharm
.

Who are some of KemPharm's key competitors?

What other stocks do shareholders of KemPharm own?

Who are KemPharm's key executives?

KemPharm's management team includes the following people:
  • Dr. Travis C. Mickle, Co-Founder, Chairman, Pres & CEO (Age 46)
  • Dr. Sven Guenther, Exec. VP of R&D (Age 47)
  • Mr. Gordon K. Johnson, Chief Bus. Officer (Age 67)
  • Ms. Christal M. M. Mickle, Co-Founder and VP of Operations & Product Devel. (Age 40)
  • Mr. R. LaDuane Clifton CPA, CFO, Sec. & Treasurer (Age 47)

When did KemPharm IPO?

(KMPH) raised $60 million in an IPO on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

How do I buy shares of KemPharm?

Shares of KMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is KemPharm's stock price today?

One share of KMPH stock can currently be purchased for approximately $0.54.

How big of a company is KemPharm?

KemPharm has a market capitalization of $39.15 million and generates $12.84 million in revenue each year. The specialty pharmaceutical company earns $-24,520,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. KemPharm employs 33 workers across the globe.

What is KemPharm's official website?

The official website for KemPharm is www.kempharm.com.

How can I contact KemPharm?

KemPharm's mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The specialty pharmaceutical company can be reached via phone at 321-939-3416 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.